Literature DB >> 28134694

Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET.

Kirsten Bouchelouche1, Mikkel Holm Vendelbo.   

Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and the expression increases with tumor aggressiveness, metastatic disease, and recurrence. Despite its name, PSMA is also expressed in neovasculature of other tumors including lung cancer. Here, we demonstrate a case of increased PSMA expression on Ga-PSMA PET/CT in benign lung opacities and bronchiectasis in a prostate cancer patient. Thus, increased PSMA activity in the lungs may be due to both benign and malignant diseases and warrants further evaluation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28134694     DOI: 10.1097/RLU.0000000000001568

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  7 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 2.  Advances in prostate-specific membrane antigen PET of prostate cancer.

Authors:  Kirsten Bouchelouche; Peter L Choyke
Journal:  Curr Opin Oncol       Date:  2018-05       Impact factor: 3.645

Review 3.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 4.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

5.  E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Authors:  Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-19       Impact factor: 9.236

6.  68 Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer.

Authors:  Jonathan Damjanovic; Jan-Carlo Janssen; Christian Furth; Gerd Diederichs; Thula Walter; Holger Amthauer; Marcus R Makowski
Journal:  Cancer Imaging       Date:  2018-05-16       Impact factor: 3.909

7.  Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.

Authors:  Dharmender Malik; Apurva Sood; Bhagwant Rai Mittal; Harmandeep Singh; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Shrawan Kumar Singh
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.